|
|
||||||||
Ann Thorac Surg 2002;73:1027
© 2002 The Society of Thoracic Surgeons
a Intensive Care Unit (Austin Campus), Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
e-mail: rb{at}austin.unimelb.edu.au
To the Editor
We appreciate the comments by Drs Christenson and Cohen. However, we believe we might have been misunderstood. We agree entirely with the correspondents that intraaortic balloon pump (IABP) and inotropic drugs are often needed to support the heart after surgery and do not intend to imply that IABP induces an increase in lactate production. Indeed, we strongly advocate the use of IABP under circumstances of low cardiac output. The aim of our article was not to link IABP and lactate production but to find a simple, early, clinically available way of detecting patients who are so sick that, despite inotropic support and IABP, they will go on to die [1]. If patients whose expected mortality, despite IABP support, is still close to 100% can be indentified early, then more advanced extracorporeal life support (ECMO or VADs) can be applied rather than persisting with a strategy which is insufficient to meet the patients physiological needs [2].
The presence of a high lactate (greater than 10 mmol/L) in the first few hours of postoperative support in patients already on IABP is a useful marker of patients who need more advanced support. Thus, we strongly support the use of IABP in selected patients but also stand by our conclusion that in a postoperative patient who is already on inotropic support and IABP, the development of a lactate greater than 10 mmol/L should trigger strong consideration of more advanced mechanical cardiovascular support.
References
Related Articles
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |